7 withdrawn. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 7 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma Elotuzumab, Selinexor, and Dexamethasone (ESd) - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Tulane University School of Medicine | 2022-04-27 | 2022-05-04 | |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma Rapid Infusion Isatuximab - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Thomas Martin, MD | 2021-05-28 | 2022-07-07 | |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant carfilzomib, dexamethasone, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Withdrawn | Mayo Clinic | 2013-08-01 | 2016-12-19 | |
| Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, bortezomib - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2023-01-05 |
Multiple Myeloma (7) · Blast Crisis (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Cytokine Release Syndrome (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1)
Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Vascular Diseases (7) · Pathologic Processes (3)
Dexamethasone (2) · Tacrolimus (2) · Transplantation (2) · Whole-Body Irradiation (2) · Antilymphocyte Serum (1) · Biopsy (1) · Bortezomib (1) · Calcium Dobesilate (1) · Cord Blood Stem Cell Transplantation (1) · Cyclophosphamide (1) · Disulfides (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Melphalan (1) · Mycophenolic Acid (1)
Mayo Clinic (2) · Jack Khouri, MD (1) · National Cancer Institute (NCI) (1) · Thomas Martin, MD (1) · Tulane University School of Medicine (1) · University of Medicine and Dentistry of New Jersey (1)
United States (3)
Hana Safah, MD (1) · Jack Khouri, MD (1) · James L. Slack, M.D. (1) · Martha Q. Lacy, M.D. (1) · Nilofer S Azad (1) · Roger Strair (1) · Shaji Kumar (1) · Thomas Martin, MD (1)
PMID 23927993, PMID 28148715, PMID 31433920
P30CA015083 (1), P30CA072720 (1), U10CA180820 (1)